Alzheimers drugs market
Alzheimer’s Drugs Market, by Drug (Donepezil, Rivastigmine, Galantamine and Memantine), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region - Global Forecast to 2025
- Mar 2018
- CMI1373
- 180 Pages
- Excel & Pdf
- Pharmaceutical
Alzheimer’s Drugs Market - Young Prospect for Aging Patient
Alzheimer’s is a form of dementia, which affect behavior, thinking, and memory of patient. The progression of disease is slow and it degrades neurons associated with learning part of cerebrum. It is most common and largest form of dementia (more than 60%), which is observed in people of age 65 and above. Accumulation of protein called as beta amyloid in spaces between nerve cells due to genetic mutation is major cause of Alzheimer. Although Alzheimer’s disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in Alzheimer’s disease.
The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is expected to witness a CAGR of 9.5% over the forecast period (2017 - 2025).
Figure 1. Global Alzheimer’s Drugs Market (US$ Bn), by Region, 2016
Source: Coherent Market Insights
Increasing prevalence of Alzheimer’s disease to drive growth of the Alzheimer’s drugs market worldwide
Increasing prevalence and incidence of Alzheimer’s disease worldwide is expected to drive the growth of Alzheimer’s disease therapeutics market. According to World Alzheimer Report in 2016, an estimated 46.5 million people were suffering from Alzheimer’s disease and the number is projected to reach 50 million by 2017, every three second there is new patient of Alzheimer’s disease worldwide.
Increasing age and aging global population are major risk factors for Alzheimer’s, which increase the disease incidence and provide growth opportunity for Alzheimer’s treatment market. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, an estimated 962 million people are of age 60 or above, which accounted for 13 per cent of the global population. The number is projected to reach 1.4 billion by 2030, growing with annual rate of 3 percent. Europe currently has highest geriatric population (25% of population), Asia Pacific had geriatric population of 547 million people and it is projected to reach 900 million by 2025, therefore these regions have potential opportunity for growth of the market. India has more than 1 million cases of Alzheimer’s disease annually. North America holds dominant position in the Alzheimer’s disease therapeutics market with estimated 5.5. Mn patients in 2017. The robust healthcare infrastructure in the region, and the region being an early adopter of novel technologies, positions it as a major market for Alzheimer’s disease.
Large number of undiagnosed patient’s and revised diagnostic guidelines to propel growth for Alzheimer’s drugs market
People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.
Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Key Highlights
- Pipeline Analysis
- Regulatory Guidelines
- Epidemiology
- Global Alzheimer’s Drugs Market, By Drugs, 2015 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Segment Trends
- Donepezil
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Rivastigmine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Galantamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Memantine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Global Alzheimer’s Drugs Market, By Distribution Channel, 2015 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- e-Commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Global Alzheimer’s Drugs Market, By Region, 2015 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2016 – 2025
- North America
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drugs, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2015 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2015 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profiles
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Janssen Pharmaceutical.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Teva Pharmaceuticals ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Eisai Co Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Lundbeck A/S.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Daichi Sankyo Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Developments
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 48 market data tables and 28 figures on "Alzheimer’s Drugs Market - Global forecast to 2025”.